Zinc in depression: a meta-analysis W Swardfager, N Herrmann, G Mazereeuw, K Goldberger, T Harimoto, ... Biological psychiatry 74 (12), 872-878, 2013 | 290 | 2013 |
A programmable encapsulation system improves delivery of therapeutic bacteria in mice T Harimoto, J Hahn, YY Chen, J Im, J Zhang, N Hou, F Li, C Coker, K Gray, ... Nature Biotechnology 40 (8), 1259-1269, 2022 | 114 | 2022 |
Enhancing the tropism of bacteria via genetically programmed biosensors T Chien, T Harimoto, B Kepecs, K Gray, C Coker, N Hou, K Pu, T Azad, ... Nature biomedical engineering 6 (1), 94-104, 2022 | 82 | 2022 |
Active matter S Tibbits MIT press, 2017 | 60 | 2017 |
Respiratory‐related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005–2012) compared to other international registries B Paes, I Mitchell, A Li, T Harimoto, KL Lanctôt Journal of Immunology Research 2013 (1), 917068, 2013 | 51 | 2013 |
Predictors of readmission to a psychiatry inpatient unit J Moss, A Li, J Tobin, IS Weinstein, T Harimoto, KL Lanctôt Comprehensive Psychiatry 55 (3), 426-430, 2014 | 50 | 2014 |
Rapid screening of engineered microbial therapies in a 3D multicellular model T Harimoto, ZS Singer, OS Velazquez, J Zhang, S Castro, TE Hinchliffe, ... Proceedings of the National Academy of Sciences 116 (18), 9002-9007, 2019 | 40 | 2019 |
Risk factors for progression of Alzheimer disease in a Canadian population: the Canadian Outcomes Study in Dementia (COSID) N Herrmann, T Harimoto, R Balshaw, KL Lanctôt, ... The Canadian Journal of Psychiatry 60 (4), 189-199, 2015 | 36 | 2015 |
Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study P Manzoni, B Paes, KL Lanctôt, A Dall’Agnola, I Mitchell, S Calabrese, ... The Pediatric infectious disease journal 36 (1), 2-8, 2017 | 33 | 2017 |
Injectable therapeutic organoids using sacrificial hydrogels NS Rossen, PN Anandakumaran, R Zur Nieden, K Lo, W Luo, C Park, ... Iscience 23 (5), 2020 | 19 | 2020 |
Bacterial therapies at the interface of synthetic biology and nanomedicine J Hahn, S Ding, J Im, T Harimoto, KW Leong, T Danino Nature Reviews Bioengineering 2 (2), 120-135, 2024 | 15 | 2024 |
Engineering bacteria for cancer therapy T Harimoto, T Danino Emerging topics in life sciences 3 (5), 623-629, 2019 | 13 | 2019 |
A rapid screening platform to coculture bacteria within tumor spheroids T Harimoto, D Deb, T Danino Nature protocols 17 (10), 2216-2239, 2022 | 12 | 2022 |
Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer D Deb, Y Wu, C Coker, T Harimoto, R Huang, T Danino Scientific Reports 12 (1), 21551, 2022 | 3 | 2022 |
Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug AR Decker-Farrell, SA Sastra, T Harimoto, MC Hasselluhn, CF Palermo, ... bioRxiv, 2024.05. 02.592216, 2024 | 1 | 2024 |
Abstract B015: Toxin-producing bacterial therapy limits tumor growth in autochthonous mouse models of pancreatic ductal adenocarcinoma AR Decker-Farrell, SA Sastra, T Harimoto, MC Hasselluhn, F Li, R Vincent, ... Cancer Research 84 (2_Supplement), B015-B015, 2024 | | 2024 |
Toxin-producing bacterial therapy limits tumor growth in autochthonous mouse models of pancreatic ductal adenocarcinoma AR Decker-Farrell, SA Sastra, T Harimoto, MC Hasselluhn, F Li, R Vincent, ... CANCER RESEARCH 84 (2), 2024 | | 2024 |
411 Programming immunogenicity of bacterial cancer therapy with biosensor-driven encapsulation systems J Hahn, T Harimoto, YY Chen, F Liguori, T Danino Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma. AR Decker, T Harimoto, SA Sastra, T Danino, K Olive CANCER RESEARCH 82 (22), 74-75, 2022 | | 2022 |
Abstract B028: Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma AR Decker, T Harimoto, SA Sastra, T Danino, K Olive Cancer Research 82 (22_Supplement), B028-B028, 2022 | | 2022 |